Slide 1: Corporate Presentation June 2023
Corporate Presentation June 2023 Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
This presentation contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this presentation, including, among others, statements r
Slide 3: Engineered Cells as Medicines
Sana’s ambition is to repair or replace any cell in the body. Technologies address fundamental barriers: Hypoimmune (HIP) technology: Overcoming immune rejection of allogeneic cells Fusogen technology: In vivo delivery of genomic modification reagents in a cell-specific manner Overcoming immune reje
Slide 4: Pipeline poised to deliver multiple clinical data readouts over next several years
Pipeline poised to deliver multiple clinical data readouts over next several years Sana’s platforms, technology, and programs 1IST, investigator sponsored trial. Abbreviations: ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; HD, Huntington’s disease; IND, investigational new dr
Slide 5: Sana's hypoimmune solution: Leverage insights from nature
Sana’s hypoimmune solution: Leverage insights from nature Abbreviations: MHC, major histocompatibility complex. Current clinical platform with multiple ongoing approaches in research phase. Leverage insights from nature to create hypoimmune cells Sana’s hypoimmune approach + CD47 - MHC I - MHC II He
Slide 6: Sana's team has pioneered hypoimmune technology
Sana’s team has pioneered hypoimmune technology
Slide 7: Hematologic cancers continue to have a high unmet need
Challenges Autologous CAR T cell scalability Many patients fail CAR T treatment Allogeneic CAR T cells immune rejection limits persistence and efficacy Opportunity Known targets Known efficacy and safety bar Sana’s HIP CAR T platform can address challenges and exploit opportunities Hematologic cance
Slide 8: Sana's HIP platform can create a regenerative pipeline for allogeneic CAR T therapies
Sana’s HIP platform can create a regenerative pipeline for allogeneic CAR T therapies 1~450 doses assumes the middle dose in the ARDENT Phase 1 study and ~950 doses assumes an autoimmune dose consistent with public data on current autoimmune dose levels. Abbreviations: Cas12b, CRISPR associated prot
Slide 9: HIP CD19 CAR T cells demonstrate persistence and continued efficacy in humanized mice model
D55 D87 D75 D83 SC291 tumor control comparable at early timepoints to standard CD19 CAR T cells SC291 tumor control superior at later timepoints to standard CD19 CAR T cells SC291 controls tumors when animals are rechallenged with tumor HIP CD19 CAR T cells demonstrate persistence and continued effi
Slide 10: ARDENT trial will provide rapid insight into hypoimmune immune evasion
ARDENT trial will provide rapid insight into hypoimmune immune evasion SC291 is a mixture of HIP and non-HIP CAR T cells HIP CAR T cells survive after immune recovery T cells and NK cells recover Triple Knockout and CAR expression: 40-50% are fully modified cells Non-HIP cells eliminated by patient
Slide 11: CAR T cells remain detectable in the majority of patients in ZUMA-1 trial
Locke et al. Lancet Oncology. 2019 CAR T cells remain detectable in the majority of patients with ongoing response treated in ZUMA-1 trial Patients with CAR gene-marked cells (%) Month n=37 n=37 n=33 n=34 n=34 n=33 n=31 n=32
Slide 12: SC291: Sana's CD19 HIP allogeneic CAR T
SC291: Sana’s CD19 HIP allogeneic CAR T First clinical data in 2023 Data show CAR T cell persistence correlates with long term complete response (CRs) rates1 Improved persistence can lead to best-in-class allogeneic CAR T platform CAR T Persistence Potential Efficacy Outcome ≤ 1 month Comparable to
Slide 13: SC262: Targeting growing population of patients with inadequate response to CD19 therapy
SC262: Targeting growing population of patients with inadequate response to CD19 therapy 1US, EU5, and Japan. 2Clarivate DRG NHL Market Forecast Nov 2021; 2027 Forecast is 2L+ LBCL patients; internal analysis of secondary EPI data. 3Di Blasi et al. Blood.2022; DESCAR-T registry. ~65% ~35% 100% ~12K
Slide 14: SC262: Licensed CD22 CAR produced strong clinical data in CD19 failures
2023 DAVA Frank/Stanford SC262 Goals: File IND this year; clinical data in 2024 N=38 SC262: Licensed CD22 CAR produced strong clinical data in CD19 failures when part of autologous CAR T N=16 N=21 >50% 6-month CR rate in CD19 CAR failure DLBCL patients High rate of CRs in CD19 failure ALL patients ~
Slide 15: SC255: Licensed BCMA CAR produced strong clinical data in myeloma
SC255: Licensed BCMA CAR produced strong clinical data in myeloma when part of autologous CAR T 4 3 ORR: 98% 5 ORR: 95% ORR: 75% Total N=100 SC255 Goal: File IND as early as 2024 Prior CAR T n=12 No prior CAR T n=88 1 ~80% patients MRD negative at 12 months ~75% patients in CR/sCR with median follow
Slide 16: CAR T cells have the potential to transform autoimmune disorders
CAR T cells have the potential to transform autoimmune disorders like they have in blood cancers Depth of B-cell depletion correlates with clinical benefit CD19 CAR T cell therapy results in deep B-cell depletion Potential to deliver durable long-term remissions SC291 has the scale and potential pro
Slide 17: SC291 offers potential to address large unmet need in autoimmune disorders
SC291 product candidate offers potential to address large unmet need in various autoimmune disorders SC291: CD19 HIP allogeneic CAR T for treatment of autoimmune disorders Allogeneic HIP CAR T cell MHC I MHC II TCRα + CD19 CAR + CD47 >75 different types of autoimmune disorders with high unmet need a
Slide 18: Goal is to build a best-in-class CAR T portfolio
Goal is to build a best-in-class CAR T portfolio to treat patients with a range of cancers and beyond 1Avezbakiyev et al. Blood. 2022 2Durie et al. The Oncologist. 2020 Unlocking the potential of our allogeneic CAR T franchise across multiple patient populations Value Time CD19 CD22 BCMA Autoimmune
Slide 19: Type 1 diabetes represents a large unmet need
Disease caused by autoimmune destruction of insulin-producing beta cells in the pancreas; results in inability to control blood glucose Type 1 diabetes is a large unmet need with 1.9M patients in the U.S. and 2.4M in Europe2 Long-term complications: end-organ damage, including heart attack, stroke,
Slide 20: SC451 is an allogeneic iPSC-derived hypoimmune pancreatic islet cell therapy
Sana’s solution: SC451 is an allogeneic iPSC-derived hypoimmune pancreatic islet cell therapy Hu et al. Nature Biotechnology. 2023 Differentiate iPSCs into glucose-responsive islet cells that are hypoimmune + CD47 HLA I HLA II Hypoimmune iPSC-derived islet cells Create iPSC GMP master cell bank Star
Slide 21: Survival of allogeneic hypoimmune islet cells for 10+ months without immunosuppression
HIP results (follow up shown: 10 months). Study ongoing. D0 12 wks 28 wks 40 wks WT results (no survival after 1 wk) D0 1 wk n=1 HIP primary islet cells; n=1 WT primary islet cells. Survival of allogeneic hypoimmune pancreatic islet cells for 10+ months without immunosuppression Study design: NHP pr
Slide 22: HIP-modified allogeneic islet cells lead to normal blood glucose in diabetic NHP
HIP-modified allogeneic islet cells lead to normal blood glucose with no insulin and no immunosuppression in diabetic NHP Normal Hypoglycemia Impaired fasting glucose Hyperglycemia D78 Cell transplantation D85-D89 Reduce exogenous insulin D0 STZ D3 Start exogenous insulin Study Design (N=1) NHP prim
Slide 23: Investigator sponsored trial: primary human HIP islet cells in type 1 diabetes
Investigator sponsored trial Primary human HIP islet cells transplantation in type 1 diabetes patients Goal: Cell survival with no immunosuppression Goal: Data in 2023 Insight for SC451 Path to potential clinical validation of hypoimmune islet cells in T1DM patients in 2023 Cell survival & immune ev
Slide 24: Sana aspiration: Engineered cells as medicines
Sana aspiration: Engineered cells as medicines 1Does not incorporate hypoimmune genomic modifications Allogeneic CAR T Franchise Oncology: SC291, SC262, SC255 Autoimmune Stem Cell-Derived Type 1 Diabetes: SC451 CNS: SC3791 In vivo CAR T: SG299 Cell-specific in vivo HSC editing: SG418 Cell-specific d
Slide 25: Thank You
Thank You Sana Biotechnology www.sana.com a N a Biotechnology